Product Name
p63 (TP63), Polyclonal Antibody
Full Product Name
Polyclonal Antibody to p63
Product Synonym Names
TP63; KET; P63; P73H; P73L; TP73L; Chronic ulcerative stomatitis protein; Keratinocyte transcription factor KET; TP63; Transformation-related protein 63; p73L; Tumor protein p73-like; p40; p51; Antibody to p63; Anti-p63 Antibody; p63 Antibody
Product Gene Name
anti-TP63 antibody
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9H3D4
Purity/Purification
Purified
Protein A Chromatography
Form/Format
25 ug in 50 ul/100 ug in 200 ul PBS containing 0.05%?BSA and 0.05% sodium azide. Sodium azide is highly toxic.
Immunogen Information
A partial length recombinant p63 protein (amino acids 1-202) was used as the immunogen for this antibody.
Preparation and Storage
Store the antibody at 4 degree C, stable for 6 months.
For long-term storage, store at -20 degree C.
Avoid repeated freeze and thaw cycles.
Other Notes
Small volumes of anti-TP63 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Product Categories/Family for anti-TP63 antibody
Antibodies; Cancer Marker
Applications Tested/Suitable for anti-TP63 antibody
Western Blot (WB)
Application Notes for anti-TP63 antibody
WB: 2-4 ug/ml
Western Blot (WB) of anti-TP63 antibody
Fig-1: Western blot analysis of?p63?. Anti-?p63??antibody (11-7525) was used at 4 ug/ml on A375 lysate.

NCBI/Uniprot data below describe general gene information for TP63. It may not necessarily be applicable to this product.
NCBI Accession #
Q9H3D4.1
[Other Products]
UniProt Primary Accession #
Q9H3D4
[Other Products]
UniProt Secondary Accession #
O75080; O75195; O75922; O76078; Q6VEG2; Q6VEG3; Q6VEG4; Q6VFJ1; Q6VFJ2; Q6VFJ3; Q6VH20[Other Products]
UniProt Related Accession #
Q9H3D4[Other Products]
Molecular Weight
65,288 Da
NCBI Official Full Name
Tumor protein 63
NCBI Official Synonym Full Names
tumor protein p63
NCBI Official Symbol
TP63??[Similar Products]
NCBI Official Synonym Symbols
AIS; KET; LMS; NBP; RHS; p40; p51; p63; EEC3; OFC8; p73H; p73L; SHFM4; TP53L; TP73L; p53CP; TP53CP; B(p51A); B(p51B)
??[Similar Products]
NCBI Protein Information
tumor protein 63
UniProt Protein Name
Tumor protein 63
UniProt Synonym Protein Names
Chronic ulcerative stomatitis protein; CUSP; Keratinocyte transcription factor KET; Transformation-related protein 63; TP63; Tumor protein p73-like; p73L; p40; p51
Protein Family
Tumor protein
UniProt Gene Name
TP63??[Similar Products]
UniProt Synonym Gene Names
KET; P63; P73H; P73L; TP73L; p63; CUSP; TP63; p73L??[Similar Products]
NCBI Summary for TP63
This gene encodes a member of the p53 family of transcription factors. The functional domains of p53 family proteins include an N-terminal transactivation domain, a central DNA-binding domain and an oligomerization domain. Alternative splicing of this gene and the use of alternative promoters results in multiple transcript variants encoding different isoforms that vary in their functional properties. These isoforms function during skin development and maintenance, ***** stem/progenitor cell regulation, heart development and premature aging. Some isoforms have been found to protect the germline by eliminating oocytes or testicular germ cells that have suffered DNA damage. Mutations in this gene are associated with ectodermal dysplasia, and cleft lip/palate syndrome 3 (EEC3); split-hand/foot malformation 4 (SHFM4); ankyloblepharon-ectodermal defects-cleft lip/palate; ADULT syndrome (acro-dermato-ungual-lacrimal-tooth); limb-mammary syndrome; Rap-Hodgkin syndrome (RHS); and orofacial cleft 8. [provided by RefSeq, Aug 2016]
UniProt Comments for TP63
p63: Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter. Binds DNA as a homotetramer. Isoform composition of the tetramer may determine transactivation activity. Isoforms Alpha and Gamma interact with HIPK2. Interacts with SSRP1, leading to stimulate coactivator activity. Isoform 1 and isoform 2 interact with WWP1. Interacts with PDS5A. Isoform 5 (via activation domain) interacts with NOC2L. Widely expressed, notably in heart, kidney, placenta, prostate, skeletal muscle, testis and thymus, although the precise isoform varies according to tissue type. Progenitor cell layers of skin, breast, eye and prostate express high levels of DeltaN-type isoforms. Isoform 10 is predominantly expressed in skin squamous cell carcinomas, but not in normal skin tissues. Belongs to the p53 family. 12 isoforms of the human protein are produced by alternative promoter.
Protein type: DNA-binding; Transcription factor
Chromosomal Location of Human Ortholog: 3q28
Cellular Component: cytoplasm; cytosol; dendrite; nuclear chromatin; nucleoplasm; nucleus; transcription factor complex
Molecular Function: damaged DNA binding; double-stranded DNA binding; identical protein binding; p53 binding; protein binding; sequence-specific DNA binding; transcription factor activity; WW domain binding
Biological Process: apoptosis; DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; G1 DNA damage checkpoint; negative regulation of apoptosis; negative regulation of transcription from RNA polymerase II promoter; negative regulation of transcription, DNA-dependent; positive regulation of Notch signaling pathway; positive regulation of osteoblast differentiation; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription, DNA-dependent; protein homotetramerization; regulation of apoptosis; regulation of epidermal cell division; regulation of neuron apoptosis; response to gamma radiation; response to X-ray
Disease: Adult Syndrome; Ankyloblepharon-ectodermal Defects-cleft Lip/palate; Ectrodactyly, Ectodermal Dysplasia, And Cleft Lip/palate Syndrome 3; Limb-mammary Syndrome; Rapp-hodgkin Syndrome; Split-hand/foot Malformation 4
Research Articles on TP63
1. DeltaNp63alpha is a vital epithelial-mesenchymal transition repressor in cervical squamous cell carcinoma cells. SCC patients with low DeltaNp63alpha expression and high EMT level show more frequent metastasis and recurrence as well as reduced overall survival. The miR-205/ZEB1 axis is involved in the inhibition effect of DeltaNp63alpha on EMT.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.